Table 3.
Univariate and multivariate analysis for relapse‐free survival (Cox proportional hazards model)
| Variables | Value | Univariate analysis | Multivariate analysis | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| HR | 95%CI | P‐value | n | HR | 95%CI | P‐value | n | |||
| Age at biopsy | (ref = ≤50) | >50 | 0.87 | 0.27–3.86 | 0.84 | 49 | 48 | |||
| Menopausal state | (ref = Pre) | Post | 0.71 | 0.22–3.15 | 0.62 | 49 | ||||
| Tumor size (cm) | (ref = ≤2) | >2 | 2.32 | 0.79–8.39 | 0.12 | 49 | ||||
| Nodal status | (ref = 0) | >1 | 1.49 | 0.50–4.15 | 0.45 | 49 | ||||
| Lymphovascular invasion | (ref = No) | Yes | 1.86 | 0.67–5.33 | 0.22 | 49 | ||||
| Histopathology | (ref = Others)† | Invasive ductal | 1.27 | 0.35–3.75 | 0.68 | 49 | ||||
| Histological Grade | (ref = 1,2) | 3 | 3.05 | 0.96–13.44 | 0.057 | 49 | 2.69 | 0.71–17.5 | 0.15 | |
| Ki67 (MIB1) LI | (ref = ≤14%) | >14% | 1.86E+09 | 1.71–1.71 | 0.0121‡ | 48 | 2.25E+09 | 1.15 | 0.040‡ | |
| AR (IHC) | (ref = HS10) | ≥HS10 | 0.31 | 0.07–1.006 | 0.051 | 49 | 0.53 | 0.11–1.84 | 0.34 | |
| pAR | (ref = IS 1 | ≥IS 2 | 0.16 | 0.009–0.82 | 0.024‡ | 49 | 2.6 | 0.11–28.7 | 0.47 | |
| PIK3CA mutation of cfDNA | ||||||||||
| Total | (ref = Wild type) | 3.88E‐10 | 0.28–0.28 | 0.0006‡ | 49 | 2.01E‐10 | 8.41e‐60–0.19 | 0.0003‡ | ||
| Kinase domain | (ref = Others) | 1.48E‐09 | 0.612–0.612 | 0.014‡ | 49 | |||||
| Helical domain | (ref = Others) | 5.10E‐10 | 0.54–0.54 | 0.0099‡ | 49 | |||||
| Chemotherapy | (ref = No) | Yes | 3.12 | 0.99–13.7 | 0.0519 | 49 | ||||
†Others include 2 invasive lobular carcinomas, 3 metaplastic carcinomas, 3 apocrine carcinomas, 2 medullary carcinomas, 1 spindle cell carcinoma and 2 squamous cell carcinomas. ‡Factor showing statistical significance. AR, androgen receptor; cfDNA, cell‐free DNA; HR, hazard ratio; HS, Histoscore; IHC, immunohistochemistry; IS, intensity score; LI, labeling index; pAR, AR phosphorylation at serine‐213/210; 95%CI, 95% confidence interval.